Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of “Hold” by Brokerages

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given an average recommendation of “Hold” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.39.

A number of equities analysts recently issued reports on RVNC shares. StockNews.com assumed coverage on shares of Revance Therapeutics in a research report on Tuesday, January 21st. They issued a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays decreased their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Finally, Mizuho lowered their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th.

Revance Therapeutics Trading Down 0.5 %

Shares of NASDAQ RVNC opened at $3.65 on Friday. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.56. The company has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.86. The stock has a 50 day simple moving average of $3.42 and a 200-day simple moving average of $4.58.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. Sell-side analysts forecast that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sei Investments Co. boosted its holdings in shares of Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 7,628 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Revance Therapeutics by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 7,890 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Revance Therapeutics by 29.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 9,601 shares during the period. FORA Capital LLC purchased a new position in Revance Therapeutics during the 3rd quarter worth approximately $54,000. Finally, Creative Planning acquired a new stake in Revance Therapeutics during the 3rd quarter valued at $56,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.